Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 185× · first seen 08-sep-2026 · last seen 16-nov-2026

Senolytics

Current understanding

Dasatinib+quercetin, fisetin and successors — clearing senescent cells; early human trials underway.

Evidence log

Open questions

Related

Contributing findings

pubmed review
Cellular senescence and the hallmarks of ageing: Evaluating evidence for a causal mechanistic role.
13-nov-2026 novelty 3 per-area 2 mentions
rss news report mechanism-plausible
The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells
12-nov-2026 novelty 3 per-area 3 strengthens
pubmed review
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026 novelty 2 per-area 2 strengthens
pubmed review
The neuro-inflammaging triangle: a self-amplifying circuit of protein pathology, senescence-associated secretory phenotype and innate immunity in neurodegenerative disease.
10-nov-2026 novelty 3 per-area 2 mentions
rss news report animal-model
A Supplement Kills Senescent Cells and Extends Life in Mice
10-nov-2026 novelty 4 per-area 4 strengthens
rss news report mechanism-plausible
Cepharanthine Identified as a Novel Senolytic
10-nov-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
09-nov-2026 novelty 3 per-area 3 strengthens
pubmed preclinical animal-model
Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.
02-nov-2026 novelty 4 per-area 4 strengthens
pubmed preclinical animal-model
Enabling Photoacoustic Imaging and Photothermal Elimination of Senescent Cells via an Activatable Theranostic Probe.
01-nov-2026 novelty 3 per-area 3 strengthens
pubmed preclinical animal-model
Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.
01-nov-2026 novelty 4 per-area 4 strengthens
pubmed review mechanism-plausible
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
29-oct-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.
23-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
09-oct-2026 novelty 3 per-area 2 mentions
pubmed review
Organoids for modeling cellular senescence and age-related pathology: From experimental reconstruction to mechanistic and translational applications.
08-oct-2026 novelty 2 per-area 2 mentions
pubmed review expert-opinion
Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.
08-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026 novelty 2 per-area 2 mentions
pubmed review expert-opinion
Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.
07-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Treatment benefit does not establish senolysis or lifespan extension.
06-oct-2026 novelty 2 per-area 2 weakens
rss review
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics
06-oct-2026 novelty 2 per-area 2 strengthens
rss preclinical
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.
05-oct-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
Senotherapeutic potential against xeroderma pigmentosum.
05-oct-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
Orthogonal Light- and Enzyme-Triggered and-Gate Prodrugs for Senolytic Therapy.
04-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Immunosenescence in tumor progression: from synergistic mechanisms to therapeutic strategies.
03-oct-2026 novelty 2 per-area 2 mentions
pubmed review
Cellular senescence: six decades of discovery and reinvention.
02-oct-2026 novelty 2 per-area 2 strengthens
pubmed review mechanism-plausible
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.
01-oct-2026 novelty 3 per-area 3 strengthens
pubmed preclinical animal-model
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
01-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
The Intersection of Immunosenescence, Cellular Senescence, and Type 1 Diabetes: Paving the Way for Future Interventions.
01-oct-2026 novelty 3 per-area 2 mentions
pubmed review
Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.
01-oct-2026 novelty 2 per-area 3 strengthens
pubmed trial early human-rct
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
01-oct-2026 novelty 4 per-area 4 strengthens
pubmed preclinical animal-model
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026 novelty 4 per-area 4 strengthens
clinicaltrials trial early expert-opinion
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
30-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
Wound Healing, Senescence, and Senotherapeutics.
30-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
Crosstalk between exosomes and cellular senescence: A core vicious loop promoting α-synuclein pathology in Parkinson's disease.
30-sep-2026 novelty 2 per-area 2 strengthens
rss preclinical
uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
29-sep-2026 novelty 4 per-area 4 strengthens
pubmed review mechanism-plausible
Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.
29-sep-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.
29-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies.
27-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
T-cell senescence and immunosenescence in chronic oral mucosal inflammatory diseases: mechanisms and therapeutic implications.
27-sep-2026 novelty 2 per-area 1 mentions
clinicaltrials trial early expert-opinion
Fisetin to Improve Vascular Function in Older Adults
25-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
Senolytics for Cancer treatment: complexities and opportunities.
23-sep-2026 novelty 2 per-area 2 weakens
pubmed preclinical animal-model
Engineered Extracellular Vesicle Revitalizing Macrophage Energy Metabolism for Aged Wound Repair.
23-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
The role of senescence in kidney ageing, injury and fibrosis.
23-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
Senescence-associated extracellular vesicles in skin aging and regeneration: from pathophysiology to therapeutic opportunities.
22-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.
22-sep-2026 novelty 2 per-area 3 strengthens
pubmed review
Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.
21-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
Bone Aging and Glycative Stress: Convergent and Divergent Mechanisms Driving Skeletal Deterioration.
20-sep-2026 novelty 2 per-area 2 mentions
pubmed review
3D-Printed and Biofabricated Scaffolds for Osteoporotic Bone Defect Repair: Mechanical Adaptation, Redox Control, Senescence Modulation and Osteoimmunomodulation.
19-sep-2026 novelty 3 per-area 2 mentions
pubmed review
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
mTOR signaling in aging: from causality to geroprotective interventions and hallmark-level outcomes.
19-sep-2026 novelty 2 per-area 2 mentions

build build 880 · 2bcef25 · 2026-11-18